Stock data
Prelude Therapeutics Incorporated (PRLD)
Prelude Therapeutics Incorporated (PRLD) reported revenue of US$12.14M and net income of -US$99.50M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$12.14M | — | -US$104.57M | -US$99.50M | — |
| 2024 | US$7.00M | — | -US$139.71M | -US$127.17M | — |
| 2023 | — | — | -US$132.28M | -US$121.83M | — |
| 2022 | — | — | -US$123.54M | -US$115.44M | — |
| 2021 | — | — | -US$113.73M | -US$111.69M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$5.70M | -US$13.92M | — |
| 2026-03-31 | US$4.58M | -US$10.38M | — |
| 2025-12-31 | US$5.64M | -US$16.46M | — |
| 2025-09-30 | US$6.50M | -US$19.73M | — |
| 2025-06-30 | US$0.00M | -US$31.23M | — |
| 2025-03-31 | US$0.00M | -US$32.09M | — |
| 2024-12-31 | — | -US$28.73M | — |
| 2024-09-30 | US$3.00M | -US$32.27M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.